Ranbaxy Files For Phase I Trial On First Compound From GSK Deal
This article was originally published in PharmAsia News
MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials
You may also be interested in...
MUMBAI - Two months after filing a motion to enforce subpoenas against Indian drug maker Ranbaxy, the U.S. Department of Justice has withdrawn from taking further action. "The DOJ expressed its satisfaction with the documents submitted by Ranbaxy and Parexel Consulting," a source familiar with the issue informed PharmAsia News.
SHANGHAI - The nature of business relationships between multinational pharma companies and Indian and Chinese firms varies significantly, according to a recent study released by the Ewing Marion Kauffman Foundation
Ranbaxy and GlaxoSmithKline have identified the first clinical candidate to be developed under their discovery alliance, the two firms announced April 2